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5-Fluorouracil-related encephalopathy: at least two
distinct pathogenetic mechanisms exist - reply
Sir,
We greatly appreciate Dr Valik's comments, which have provided
new information for studying the possible pathogenetic mecha-
nisms of HDFL-related encephalopathy. However, we would like
to take this opportunity to clarify some ofthe points that we raised
in the original article (Yeh et al, 1997).
The two Krebs cycles mentioned by Dr Valik, i.e. the Krebs
tricarboxylic acid cycle (Krebs citric acid cycle) and the
Krebs-Henseleit urea cycle, correspond to the Krebs cycle and the
urea cycle in our article respectively. We considered that these two
simplified terms are well accepted by readers and are widely used
in the literature (Lehninger et al, 1993a,b; Mayes et al, 1993;
Rodwell et al, 1993). We believed that the metabolic
encephalopathy observed by us was a new pathogenetic entity,
which differed significantly from the more common hepatic
encephalopathy. Therefore, we chose not to use the traditional
clinical grading system for hepatic encephalopathy (Sherlock et al,
1954, 1989). We have indeed documented that none ofourpatients
had hepatic or renal dysfunction in terms of the conventional
biochemical criteria (Yeh et al, 1997). Also, none of them had
hypoglycaemia.
The relatively high overall incidence (5.7%) of HDFL-related
encephalopathy in our patients did not necessarily imply a genetic
basis for this condition. Instead, all our evidence has indicated that
dihydropyrimidine dehydrogenase (DPD) deficiency, even in its
incomplete form, is probably not the pathogenetic mechanism of
HDFL-related encephalopathy. 5-FU treatment in patients with
DPD deficiency should result in severe mucosal and haemato-
logical toxicities (Tuchman et al, 1985; Diasio et al, 1988), which
were definitely not observed in all our 16 patients. Also, the
encephalopathy due to DPD deficiency should characteristically
present at the first exposure to drug, and should have low or no
catabolic products (such as ammonia) of 5-FU (Tuchman et al,
1985; Diasio et al, 1988; Takimoto et al, 1996). Among our 16
patients, the encephalopathy developed at the first exposure to
HDFL in eight patients, but developed at or after the second expo-
sure in another eight patients. On rechallenge with HDFL, only
8 out of 12 patients developed recurrent encephalopathy. These
observations strongly argued that DPD deficiency is the cause of
HDFL-related encephalopathy.
We suggest that there are at least two distinct pathogenetic enti-
ties of 5-FU-related encephalopathy. The first is the 'DPD defi-
ciency type'. DPD deficiency results in failure of the first step of
5-FU catabolism and leads to 5-FU accumulation (Tuchman et al,
1985; Diasio et al, 1988; Takimoto et al, 1996). High concentration
of5-FU penetrates into cerebrospinal fluid (CSF) and causes acute
demyelination of the neurons. After discontinuation of 5-FU, it
usually takes weeks to months for remyelination to occur (Kerr et
al, 1984; Takimoto et al, 1996). High plasma level of5-FU should
also cause severe gastrointestinal (GI) and marrow toxicities
(Tuchman et al, 1985; Diasio et al, 1988; Takimoto et al, 1996).
And few or no catabolites (FUPA, 5-fluoroureidopropionic acid;
FBAL, 2-fluoro-fi-alanine; ammonia, etc.) should be detected
because ofthe failure of5-FU catabolism. The second is the '5-FU
catabolite type' (Yeh et al, 1997). The major catabolic pathway of
5-FU is intact. However, the relatively large dose
of 5-FU results in transient accumulation of 5-FU catabolites
(including ammonia). If the disposal of the latter is not adequate,
such as under conditions of malnutrition and/or impaired Krebs
cycle, transient encephalopathy ensues. No demyelinating changes
and no severe GI or marrow toxicities should be observed, and
recovery from encephalopathy usually occurs within a few days
(Yeh et al, 1997). Theoretically, a specific DPD inhibitor (such as
5-ethynyluracil) may protect the patients from the encephalopathy
ofthe 5-FU catabolite type (Davis et al, 1994).
We, however, cannot completely exclude other possible mecha-
nisms ofthe hyperammonaemia observed in our patients. The one
raised by Dr Valik, which hypothesized that a stress situation
superimposed on a genetically altered background in urea cycle
(i.e. incomplete form of urea cycle enzyme deficiencies, such as
ornithine transcarbamoylase deficiency) is certainly a possibility
that deserves further exploration (Sinatra et al, 1975; Snodgrass et
al, 1976). We also agree with Dr Valik that patients with HDFL-
related encephalopathy should have an examination of plasma
amino acids (glutamine, arginine, etc.) and the intermediates of
urea cycle (ornithine, citrulline, argininosuccinate, etc.) (Rodwell
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et al, 1993; Lehninger et al, 1993b). This may help further clarify
the pathogenetic mechanisms. And, along the same line, a detailed
pharmacogenetic study is also indicated.
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